CLSN Awaits Data In Q4, INFI Hits A Milestone, JAZZ Gets FDA Date

(RTTNews) - Cellceutix Corp.'s (CTIX.OB) phase II clinical trial of its oral drug candidate Prurisol for psoriasis has now enrolled approximately 50% of the targeted 100 patients. Full enrollment in the trial is expected to be completed by the end of 2015.

CTIX.OB closed Wednesday's trading at $1.46, up 2.82%.

Celsion Corp. (CLSN) has enrolled the first patient in its phase Ib dose escalating clinical trial evaluating the combination of GEN-1, the company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed ovarian cancer patients who will undergo neoadjuvant chemotherapy.

Interim findings from this open label study, dubbed OVATION, are expected in the fourth quarter of 2015.

CLSN closed Wednesday's trading at $1.67, down 4.02%.

Infinity Pharmaceuticals Inc. (INFI) is all set to receive a $130 million milestone payment from its partner AbbVie Inc. (ABBV), following completion of patient enrollment in a phase II study of Duvelisib in indolent non-hodgkin lymphoma.

The study, dubbed DYNAMO, has enrolled 120 patients. Infinity expects to report topline data from DYNAMO in the third quarter of 2016.

INFI closed Wednesday's trading at $8.45, up 6.62%.

Jazz Pharmaceuticals plc's (JAZZ) New Drug Application for Defibrotide for the treatment of patients with hepatic veno-occlusive disease has been accepted for Priority Review by the FDA - with a decision date set for March 31, 2016.

Hepatic VOD is a rare, early and life-threatening complication of hematopoietic stem-cell transplantation, or HSCT.

HSCT is a potentially curative procedure to treat patients with malignant and non-cancerous hematologic disorders such as leukemia, lymphoma and aplastic anemia, congenital immunodeficiencies and metabolic disorders.

JAZZ closed Wednesday's trading at $132.81, up 6.41%.

Zogenix Inc. (ZGNX) has reported positive results from a phase Ib multi-dose clinical trial of Relday for the treatment of schizophrenia. Relday is a proprietary, once-monthly subcutaneous investigational formulation of risperidone.

According to the trial results, risperidone plasma concentrations in the therapeutic range were achieved on the first day of dosing, reached steady state levels following the second dose and consistently maintained therapeutic levels throughout the four-month period.

Relday was generally safe and well-tolerated, with results consistent with the profile of risperidone and the Company's previous Phase 1 single-dose clinical trial, the company said.

With the positive top-line results from the Phase 1b multi-dose trial, Relday is now well-positioned to begin a Phase 3 program once a development and commercialization partner is secured, the company added.

ZGNX closed Wednesday's trading at $13.50, up 6.89%.